10x Genomics (NASDAQ:TXG), Inc. is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.
Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations. The company has established regional operations and support centers across North America, Europe and Asia to facilitate training, technical support and collaborations with leading research laboratories.
10x Genomics has built its reputation on enabling new discoveries in fields such as oncology, immunology, neuroscience and developmental biology. By combining microfluidics, novel chemistry and bioinformatics software, the company’s solutions aim to simplify workflow complexity and accelerate data generation and interpretation for large-scale studies.
Co-founded by Serge Saxonov, Ben Hindson and Kevin Ness, 10x Genomics continues to expand its product portfolio through ongoing research and development. The company’s integrated approach to single-cell and spatial biology is designed to empower scientists worldwide to uncover cellular heterogeneity, identify therapeutic targets and drive innovation in precision medicine.
